Proteomika a daganatkutatásban: Biomarkerek diagnosztikai és klinikai validálása szöveti multiblokk ("tissue microarray") módszerrel

Translated title of the contribution: Proteomics in oncology: Diagnostic and clinical validation of biomarkers using the tissue microarray technique

T. Krenács, Stelkovics Éva, B. Molnár, L. Kópper

Research output: Contribution to journalArticle

Abstract

Since cell functions and the effect of drug therapy are manifested at protein level, studying protein expression and functions are crucial in oncology. Our knowledge on the human genom and the high-throughput protein chip techniques allow DNA-sequence based studies of the human proteom (full set or rather a wide range of proteins). The aim of proteomics in cancer research is to assist in understanding the molecular basis of cancer development (pathogenesis). Also, they are used to discover new biomarkers for the prediction of biological behavior (prognosis) and/or therapeutic targets and response to therapy (prediction) of cancer. Biomarkers can also be molecular targets for therapy. Systemic molecular genetic (CGH, DNA-chip) and proteomic (2D PAGE, mass spectrometry, protein chip) screening techniques have revealed the differential expression of thousands of genes during tumor development and progression. Validation of these data require screening of large number of selected tumors at the cellular (in situ) level using TMAs (tissue microarrays) based on sample concentration. The advent of high-throughput proteomic methods in cancer research predicts a massive shift towards a "molecular target" approach in cancer diagnostics and therapy.

Original languageHungarian
Pages (from-to)209-222
Number of pages14
JournalOrvoskepzes
Volume81
Issue number3
Publication statusPublished - 2006

Fingerprint

Medical Oncology
Proteomics
Biomarkers
Neoplasms
Protein Array Analysis
Proteins
Electrophoresis, Gel, Two-Dimensional
Therapeutics
Oligonucleotide Array Sequence Analysis
Research
Molecular Biology
Mass Spectrometry
Gene Expression
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{654bfe35486b4c3a8bc0669920300c08,
title = "Proteomika a daganatkutat{\'a}sban: Biomarkerek diagnosztikai {\'e}s klinikai valid{\'a}l{\'a}sa sz{\"o}veti multiblokk ({"}tissue microarray{"}) m{\'o}dszerrel",
abstract = "Since cell functions and the effect of drug therapy are manifested at protein level, studying protein expression and functions are crucial in oncology. Our knowledge on the human genom and the high-throughput protein chip techniques allow DNA-sequence based studies of the human proteom (full set or rather a wide range of proteins). The aim of proteomics in cancer research is to assist in understanding the molecular basis of cancer development (pathogenesis). Also, they are used to discover new biomarkers for the prediction of biological behavior (prognosis) and/or therapeutic targets and response to therapy (prediction) of cancer. Biomarkers can also be molecular targets for therapy. Systemic molecular genetic (CGH, DNA-chip) and proteomic (2D PAGE, mass spectrometry, protein chip) screening techniques have revealed the differential expression of thousands of genes during tumor development and progression. Validation of these data require screening of large number of selected tumors at the cellular (in situ) level using TMAs (tissue microarrays) based on sample concentration. The advent of high-throughput proteomic methods in cancer research predicts a massive shift towards a {"}molecular target{"} approach in cancer diagnostics and therapy.",
keywords = "Prediction, Prognostics, Proteomics, Tissue microarray",
author = "T. Kren{\'a}cs and Stelkovics {\'E}va and B. Moln{\'a}r and L. K{\'o}pper",
year = "2006",
language = "Hungarian",
volume = "81",
pages = "209--222",
journal = "Orvoskepzes",
issn = "0030-6037",
publisher = "Semmelweis Kiado",
number = "3",

}

TY - JOUR

T1 - Proteomika a daganatkutatásban

T2 - Biomarkerek diagnosztikai és klinikai validálása szöveti multiblokk ("tissue microarray") módszerrel

AU - Krenács, T.

AU - Éva, Stelkovics

AU - Molnár, B.

AU - Kópper, L.

PY - 2006

Y1 - 2006

N2 - Since cell functions and the effect of drug therapy are manifested at protein level, studying protein expression and functions are crucial in oncology. Our knowledge on the human genom and the high-throughput protein chip techniques allow DNA-sequence based studies of the human proteom (full set or rather a wide range of proteins). The aim of proteomics in cancer research is to assist in understanding the molecular basis of cancer development (pathogenesis). Also, they are used to discover new biomarkers for the prediction of biological behavior (prognosis) and/or therapeutic targets and response to therapy (prediction) of cancer. Biomarkers can also be molecular targets for therapy. Systemic molecular genetic (CGH, DNA-chip) and proteomic (2D PAGE, mass spectrometry, protein chip) screening techniques have revealed the differential expression of thousands of genes during tumor development and progression. Validation of these data require screening of large number of selected tumors at the cellular (in situ) level using TMAs (tissue microarrays) based on sample concentration. The advent of high-throughput proteomic methods in cancer research predicts a massive shift towards a "molecular target" approach in cancer diagnostics and therapy.

AB - Since cell functions and the effect of drug therapy are manifested at protein level, studying protein expression and functions are crucial in oncology. Our knowledge on the human genom and the high-throughput protein chip techniques allow DNA-sequence based studies of the human proteom (full set or rather a wide range of proteins). The aim of proteomics in cancer research is to assist in understanding the molecular basis of cancer development (pathogenesis). Also, they are used to discover new biomarkers for the prediction of biological behavior (prognosis) and/or therapeutic targets and response to therapy (prediction) of cancer. Biomarkers can also be molecular targets for therapy. Systemic molecular genetic (CGH, DNA-chip) and proteomic (2D PAGE, mass spectrometry, protein chip) screening techniques have revealed the differential expression of thousands of genes during tumor development and progression. Validation of these data require screening of large number of selected tumors at the cellular (in situ) level using TMAs (tissue microarrays) based on sample concentration. The advent of high-throughput proteomic methods in cancer research predicts a massive shift towards a "molecular target" approach in cancer diagnostics and therapy.

KW - Prediction

KW - Prognostics

KW - Proteomics

KW - Tissue microarray

UR - http://www.scopus.com/inward/record.url?scp=35648997840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35648997840&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:35648997840

VL - 81

SP - 209

EP - 222

JO - Orvoskepzes

JF - Orvoskepzes

SN - 0030-6037

IS - 3

ER -